{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:53:04Z","timestamp":1747201984791,"version":"3.40.5"},"reference-count":39,"publisher":"Federacion Colombiana de Obstetricia y Ginecologia","issue":"3","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Colomb. Obstet. Ginecol."],"abstract":"<jats:p>Objetivo: describir la seguridad y aceptabilidad del uso del sistema intrauterino liberador de levonorgestrel de 52 mg en mujeres con hemorragia uterina anormal. Materiales y m\u00e9todos: cohorte retrospectiva en la que se incluyeron mujeres de 18 a\u00f1os o m\u00e1s con diagn\u00f3stico de hemorragia uterina anormal, reporte por ultrasonido de tama\u00f1o uterino entre 6 y 10 cm de longitud y cavidad endometrial uniforme en toda su longitud, independiente de alteraci\u00f3n estructural, a quienes se les coloc\u00f3 para tratamiento el sistema intrauterino liberador de levonorgestrel de 52 mg, en el periodo de 2012 hasta 2016. Se realiz\u00f3 un muestreo por conveniencia. Se midieron variables sociodemogr\u00e1ficas y cl\u00ednicas basales, as\u00ed como la percepci\u00f3n de la hemorragia por parte de la paciente y la frecuencia de falla, amenorrea, necesidad de histerectom\u00eda y eventos adversos, con seguimiento a 12 meses. Se aplic\u00f3 estad\u00edstica descriptiva. Resultados: se evaluaron 200 pacientes, hubo una percepci\u00f3n de mejor\u00eda subjetiva del volumen de sangrado y de la frecuencia de incapacidad laboral o asistencia a urgencias. El 90% de las pacientes registr\u00f3 amenorrea y el 6% eventos adversos. Conclusiones: el sistema intrauterino liberador de levonorgestrel de 52 mg es una alternativa segura para el manejo de la hemorragia uterina anormal en mujeres con \u00fateros de tama\u00f1o normal y sin alteraciones submucosas del endometrio. Se requieren estudios aleatorizados en el medio local para evaluar su efectividad y eficiencia respecto a otras alternativas de manejo.<\/jats:p>","DOI":"10.18597\/rcog.3547","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:19:11Z","timestamp":1602116351000},"page":"247-256","source":"Crossref","is-referenced-by-count":0,"title":["Seguridad y aceptabilidad del sistema intrauterino liberador de levonorgestrel 52 mg en mujeres con hemorragia uterina anormal en un centro de atenci\u00f3n ambulatoria en Bogot\u00e1, Colombia, 2012-2016"],"prefix":"10.18597","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3777-4291","authenticated-orcid":false,"given":"Patricia","family":"Sandoval-Vivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7913","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"86031","doi-asserted-by":"crossref","unstructured":"Munro MG, Critchley HOD, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13. https:\/\/doi.org\/10.1016\/j.ijgo.2010.11.011","DOI":"10.1016\/j.ijgo.2010.11.011"},{"key":"86032","doi-asserted-by":"crossref","unstructured":"Munro MG, Critchley HOD, Fraser IS, Haththotuwa R, Kriplani A, Bahamondes L, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143(3):393-408. https:\/\/doi.org\/10.1002\/ijgo.12666","DOI":"10.1002\/ijgo.12666"},{"key":"86033","doi-asserted-by":"crossref","unstructured":"Spencer CP, Whitehead MI. Endometrial asessment re-visited. Br J Obstet Gynaecol. 1999;106(7):623-32. https:\/\/doi.org\/10.1111\/j.1471-0528.1999.tb08358.x","DOI":"10.1111\/j.1471-0528.1999.tb08358.x"},{"key":"86034","doi-asserted-by":"crossref","unstructured":"Fraser IS, Critchley HOD, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466-76. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.01.023","DOI":"10.1016\/j.fertnstert.2007.01.023"},{"key":"86035","doi-asserted-by":"crossref","unstructured":"Fraser IS, Critchley HOD, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22(3):635-43. https:\/\/doi.org\/10.1093\/humrep\/del478","DOI":"10.1093\/humrep\/del478"},{"key":"86036","doi-asserted-by":"crossref","unstructured":"Munro MG, Critchley HOD, Fraser IS. Research and clinical management for women with abnormal uterine bleeding in the reproductive years: More than PALM-COEIN. Br J Obstet Gynaecol. 2017;124(2):185-9. https:\/\/doi.org\/10.1111\/1471-0528.14431","DOI":"10.1111\/1471-0528.14431"},{"key":"86037","unstructured":"National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: Assessment and management. NG88; March 2018. Disponible en: https:\/\/www.nice.org.uk\/guidance\/ng88."},{"key":"86038","doi-asserted-by":"crossref","unstructured":"Xiao B, Wu S-C, Chong J, Zeng T, Han L-H, Luukkainen T. Therapeutic effects of the levonorgestrelreleasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-9. https:\/\/doi.org\/10.1016\/s0015-0282(02)04913-0","DOI":"10.1016\/S0015-0282(02)04913-0"},{"key":"86039","doi-asserted-by":"crossref","unstructured":"Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: A randomized controlled trial. Obstet Gynecol. 2006;108(4):924-9. https:\/\/doi.org\/10.1097\/01.AOG.0000238343.62063.22","DOI":"10.1097\/01.AOG.0000238343.62063.22"},{"key":"86040","doi-asserted-by":"crossref","unstructured":"James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: Consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124-34. https:\/\/doi.org\/10.1016\/j.ejogrb.2011.04.025","DOI":"10.1016\/j.ejogrb.2011.04.025"},{"key":"86041","doi-asserted-by":"crossref","unstructured":"Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9:CD000400. https:\/\/doi.org\/10.1002\/14651858.CD000400.pub4","DOI":"10.1002\/14651858.CD000400.pub4"},{"key":"86042","unstructured":"ACOG. Committee opinion: Management of acute AUB in nonpregnant re-productive aged women. Obstet Gynecol. 2014;123(603):1403-7."},{"key":"86043","unstructured":"Bayer AG, Berlin G. Mirena Annotated CCDS 2014; 2014."},{"key":"86044","doi-asserted-by":"crossref","unstructured":"Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol. 2003;56(4):305-7. https:\/\/doi.org\/10.1136\/jcp.56.4.305","DOI":"10.1136\/jcp.56.4.305"},{"key":"86045","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Mirena\u00ae (levonorgestrel- releasing intrauterine system) prescribing information. 2014;1-193."},{"key":"86046","doi-asserted-by":"crossref","unstructured":"Beatty MN, Blumenthal PD. The levonorgestrelreleasing intrauterine system: Safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009\/08\/03. 2009;5(1):561-74. https:\/\/doi.org\/10.2147\/tcrm.s5624","DOI":"10.2147\/TCRM.S5624"},{"key":"86047","doi-asserted-by":"crossref","unstructured":"Bofill Rodriguez M, Lethaby A, Jordan V. Progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2020;6:CD002126. https:\/\/doi.org\/10.1002\/14651858.CD002126.pub4","DOI":"10.1002\/14651858.CD002126.pub4"},{"key":"86048","doi-asserted-by":"crossref","unstructured":"Espey E. Levonorgestrel intrauterine system\u2014firstline therapy for heavy menstrual bleeding. N Engl J Med. 2013;368(2):184-5. https:\/\/doi.org\/10.1056\/NEJMe1214191","DOI":"10.1056\/NEJMe1214191"},{"key":"86049","doi-asserted-by":"crossref","unstructured":"Benetti-Pinto CL, De S\u00e1 Rosa-E-Silva ACJ, Yela DA, J\u00fanior JMS. Sangramento uterino anormal. Rev Bras Ginecol Obstet. 2017;39(7):358-68. https:\/\/doi.org\/10.1055\/s-0037-1603807","DOI":"10.1055\/s-0037-1603807"},{"key":"86050","doi-asserted-by":"crossref","unstructured":"Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-Releasing Intrauterine Systems versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-9. https:\/\/doi.org\/10.1245\/s10434-016-5699-9.","DOI":"10.1245\/s10434-016-5699-9"},{"key":"86051","unstructured":"Food and Drug Administration (FDA). Center for Drug evaluation and research. Application number: NDA 021225 S-031."},{"key":"86052","unstructured":"Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: Current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589-598. https:\/\/doi.org\/10.2147\/IJWH.S9970522."},{"key":"86053","doi-asserted-by":"crossref","unstructured":"d\u2019Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75(6 Suppl):S2-7. https:\/\/doi.org\/10.1016\/j.contraception.2006.12.024","DOI":"10.1016\/j.contraception.2006.12.024"},{"key":"86054","doi-asserted-by":"crossref","unstructured":"Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003; 79(5):1194-8. https:\/\/doi.org\/10.1016\/S0015-0282(03)00175-4.","DOI":"10.1016\/S0015-0282(03)00175-4"},{"key":"86055","doi-asserted-by":"crossref","unstructured":"Magalh\u00e3es J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75(3):193-8. https:\/\/doi.org\/10.1016\/j.contraception.2006.11.004","DOI":"10.1016\/j.contraception.2006.11.004"},{"key":"86056","doi-asserted-by":"crossref","unstructured":"Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1):371-4. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.09.048","DOI":"10.1016\/j.fertnstert.2009.09.048"},{"key":"86057","doi-asserted-by":"crossref","unstructured":"Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The Effect of Levonorgestrel Intrauterine System on Uterine Myomas: A 1-Year Follow-up Study. J Minim Invasive Gynecol. 2008;15(6):735-8. https:\/\/doi.org\/10.1016\/j.jmig.2008.08.011","DOI":"10.1016\/j.jmig.2008.08.011"},{"key":"86058","doi-asserted-by":"crossref","unstructured":"Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95(2):497-502. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.10.009","DOI":"10.1016\/j.fertnstert.2010.10.009"},{"key":"86059","doi-asserted-by":"crossref","unstructured":"Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012;91(1):3-9. https:\/\/doi.org\/10.1111\/j.1600-0412.2011.01303.x","DOI":"10.1111\/j.1600-0412.2011.01303.x"},{"key":"86060","doi-asserted-by":"crossref","unstructured":"Desai R. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3(1):20. https:\/\/doi.org\/10.4103\/0976-7800.98812","DOI":"10.4103\/0976-7800.98812"},{"key":"86061","doi-asserted-by":"crossref","unstructured":"Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J. 1998;316(7138):1122-6. https:\/\/doi.org\/10.1136\/bmj.316.7138.1122","DOI":"10.1136\/bmj.316.7138.1122"},{"key":"86062","doi-asserted-by":"crossref","unstructured":"Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2003;(2):CD003855. https:\/\/doi.org\/10.1002\/14651858.cd003855","DOI":"10.1002\/14651858.CD003855"},{"key":"86063","doi-asserted-by":"crossref","unstructured":"Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivel\u00e4 A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. J Am Med Assoc. 2004;291(12):1456-63. https:\/\/doi.org\/10.1001\/jama.291.12.1456","DOI":"10.1001\/jama.291.12.1456"},{"key":"86064","doi-asserted-by":"crossref","unstructured":"Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-83. https:\/\/doi.org\/10.1016\/S0002-9378(11)90533-X","DOI":"10.1016\/S0002-9378(11)90533-X"},{"key":"86065","doi-asserted-by":"crossref","unstructured":"Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Canada. 2009;31(4):340-7. https:\/\/doi.org\/10.1016\/S1701-2163(16)34151-2","DOI":"10.1016\/S1701-2163(16)34151-2"},{"key":"86066","doi-asserted-by":"crossref","unstructured":"Marions L, L\u00f6vkvist L, Taube A, Johansson M, Dalvik H, \u00d8verlie I. Use of the levonorgestrel releasingintrauterine system in nulliparous women\u2014a noninterventional study in Sweden. Eur J Contracept Reprod Heal Care. 2011;16(2):126-34. https:\/\/doi.org\/10.3109\/13625187.2011.558222","DOI":"10.3109\/13625187.2011.558222"},{"key":"86067","doi-asserted-by":"crossref","unstructured":"Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virusinfected women: Z 5-year follow-up study. Am J Obstet Gynecol. 2011;204(2):126.e1-126.e4. https:\/\/doi.org\/10.1016\/j.ajog.2010.09.002","DOI":"10.1016\/j.ajog.2010.09.002"},{"key":"86068","doi-asserted-by":"crossref","unstructured":"Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: A randomized trial. Obstet Gynecol. 2005;105(4):811-5. https:\/\/doi.org\/10.1097\/01.AOG.0000156301.11939.56","DOI":"10.1097\/01.AOG.0000156301.11939.56"},{"key":"86069","doi-asserted-by":"crossref","unstructured":"Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril. 2008;90(3):673-7. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.07.1315","DOI":"10.1016\/j.fertnstert.2007.07.1315"}],"container-title":["Revista Colombiana de Obstetricia y Ginecolog\u00eda"],"original-title":[],"link":[{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3547\/3645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3547\/3645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T21:55:49Z","timestamp":1605131749000},"score":1,"resource":{"primary":{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/view\/3547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,7]]}},"URL":"https:\/\/doi.org\/10.18597\/rcog.3547","relation":{},"ISSN":["2463-0225","0034-7434"],"issn-type":[{"type":"electronic","value":"2463-0225"},{"type":"print","value":"0034-7434"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}